We found that a high HAA intake was significantly associated with an increased risk of prostate cancer (Table 3), and the NAT2 slow acetylator phenotype, the CYP1A1 GG and GA + GG genotypes, and the CYP1A2 CA, AA, and CA + AA genotypes were associated with an increased prostate cancer risk in our affected cohort with compared with the controls (Table 4). The gene discussed is NAT2; the disease is prostate carcinoma.